Clinical Intake — Rheumatoid arthritis

This 57-year-old female with seropositive rheumatoid arthritis diagnosed in 2021 presents for ongoing management of inflammatory joint disease. She failed approximately 18 months of first-line subcutaneous biologic therapy with persistent joint swelling and elevated inflammatory markers before transitioning to her current intravenous biologic regimen, now 14 administrations completed with good clinical response and well-controlled inflammatory markers (CRP 0.8 mg/dL). Concurrent anchor therapy with methotrexate continues at 15mg weekly. Comorbidities include well-managed hypertension and hypothyroidism on stable regimens. Dr. Patel refers for authorization of continued specialist-directed biologic administration.